Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
Open Access
Abstract
No abstract availableKeywords
This publication has 120 references indexed in Scilit:
- Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agentsBritish Journal of Cancer, 2012
- Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysisBMC Cancer, 2011
- Effect of Obesity on the Pharmacokinetics of Drugs in HumansClinical Pharmacokinetics, 2010
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet, 2009
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Relation between chemotherapy dose, oestrogen receptor expression, and body-mass indexThe Lancet, 2005
- Quantification of Lean BodyweightClinical Pharmacokinetics, 2005
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995